Back to top
more

Intellia Therapeutics (NTLA)

(Delayed Data from NSDQ)

$12.12 USD

12.12
3,419,380

+0.63 (5.48%)

Updated Aug 4, 2025 04:00 PM ET

Pre-Market: $12.22 +0.10 (0.83%) 9:14 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?

by Zacks Equity Research

Sector ETF report for ARKG

    Sweta Killa headshot

    Should You Invest in the ARK Innovation ETF (ARKK)?

    by Sweta Killa

    Sector ETF report for ARKK

      Zacks Equity Research

      Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?

      by Zacks Equity Research

      Sector ETF report for ARKG

        Zacks Equity Research

        Should You Invest in the ARK Innovation ETF (ARKK)?

        by Zacks Equity Research

        Sector ETF report for ARKK

          Zacks Equity Research

          Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia

          by Zacks Equity Research

          Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia

            Kevin Cook headshot

            CRISPR Science and Stocks: Knowing Enough to Invest

            by Kevin Cook

            Can you learn enough about the science and the companies to invest with confidence?

              Zacks Equity Research

              Should You Invest in the ARK Innovation ETF (ARKK)?

              by Zacks Equity Research

              Sector ETF report for ARKK

                Zacks Equity Research

                Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex

                by Zacks Equity Research

                Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex

                  Zacks Equity Research

                  Vertex/CRISPR's Sickle Disease Candidate Put on Hold by FDA

                  by Zacks Equity Research

                  FDA places clinical hold on a Vertex (VRTX) and CRISPR Therapeutics' IND application for CTX001 for the treatment of sickle cell disease.

                    David Borun headshot

                    Should You Buy the Dip in CRISPR Therapeutics?

                    by David Borun

                    A "Clinical Hold" from the FDA has the shares falling, but is it an opportunity to get in?

                      David Borun headshot

                      Is Genome Editing the Next Biotech Breakthrough?

                      by David Borun

                      CRISPR technology is promising to be the foundation the treatment of 1000s of diseases

                        Sweta Killa headshot

                        Should You Invest in the ARK Innovation ETF (ARKK)?

                        by Sweta Killa

                        Sector ETF report for ARKK

                          Zacks Equity Research

                          Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics

                          by Zacks Equity Research

                          Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics

                            Kevin Cook headshot

                            Why Sarepta (SRPT) Jumped and We Sold

                            by Kevin Cook

                            Gains have rewarded the patient, but the long-term is balanced with obstacles still ahead in the FDA gauntlet

                              Zacks Equity Research

                              Is a Surprise Coming for Intellia Therapeutics (NTLA)This Earnings Season?

                              by Zacks Equity Research

                              Intellia Therapeutics (NTLA) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

                                Kevin Cook headshot

                                Healthcare Heroes That Aren't Done Yet

                                by Kevin Cook

                                Key growth stocks across medical industries tell you the megatrends are in full force for years to come

                                  Zacks Equity Research

                                  Regeneron Announces Positive Data on Carcinoma Candidate

                                  by Zacks Equity Research

                                  Regeneron Pharmaceuticals and partner Sanofi announced positive results related to its experimental candidate, REGN2810, a checkpoint inhibitor targeting PD-1 in patients with advanced cutaneous squamous cell carcinoma (CSCC).

                                    Zacks Equity Research

                                    Novartis' (NVS) CTL109 BLA Gets Breakthrough Therapy Status

                                    by Zacks Equity Research

                                    Novartis (NVS) announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, CTL019.

                                      Zacks Equity Research

                                      Novartis' CTL109 BLA Gets Priority Review Status from FDA

                                      by Zacks Equity Research

                                      Novartis A.G. (NVS) announced that the FDA has accepted and granted priority review designation to its biologics license application (BLA) for pipeline candidate, CTL019 (tisagenlecleucel-T).